SCHEMBL15344231

SCHEMBL15344231

Cc1cccc(-c2ccc(F)cc2C)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 2/20 0.54
AKR1C3 P42330 1/20 0.44
AKR1C2 P52895 1/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
TP53 P04637 1/20 0.44
BACE1 P56817 1/20 0.43
RPS6KA3 P51812 1/20 0.41
PDE3B Q13370 2/20 0.41
PDE3A Q14432 2/20 0.41
CNR2 P34972 2/20 0.41
CNR1 P21554 1/20 0.41
NMT1 P30419 1/20 0.40
ESR2 Q92731 1/20 0.40
NPY5R Q15761 1/20 0.40
NR3C1 P04150 1/20 0.39
MEN1 O00255 1/20 0.39
MAPT P10636 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10094674 0.85 ACHE (0.54) ACHEAKR1C3AKR1C2RAB9ANPC1
SCHEMBL2236879 0.85 AKR1C3 (0.55) ACHEAKR1C3AKR1C2RAB9ANPC1
SCHEMBL14850868 0.85 ACHE (0.54) ACHERAB9ANPC1SMN1; SMN2TP53
SCHEMBL5551209 0.84 ACHE (0.48) ACHEAKR1C3AKR1C2RAB9ANPC1
SCHEMBL3756100 0.82 ESR2 (0.59) AKR1C3AKR1C2BACE1PDE3BPDE3A
SCHEMBL24329717 0.81 ACHE (0.50) ACHEAKR1C3AKR1C2RAB9ANPC1
SCHEMBL21020958 0.81 MAP4K4 (0.47) BACE1PDE3BPDE3ANMT1NPY5R
SCHEMBL16055425 0.81 ESR2 (0.55) ACHEAKR1C3AKR1C2BACE1ESR2
SCHEMBL30293697 0.81 MAP4K4 (0.47) BACE1PDE3BPDE3ANMT1NPY5R
SCHEMBL8265084 0.81 ACHE (0.54) ACHEAKR1C3AKR1C2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3473628-A1 DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR Medshine Discovery Inc. (CN) 2019-04-24 EP disclosed
EP-3070081-B1 BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION GILEAD SCIENCES INC (US) 2018-02-28 EP disclosed
WO-2017215588-A1 DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR 南京明德新药研发股份有限公司 2017-12-21 WO disclosed
EP-3181555-A1 BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE Gilead Sciences, Inc. (US) 2017-06-21 EP disclosed
US-20170088554-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2017-03-30 US disclosed
US-9464096-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2016-10-11 US disclosed
US-20160152582-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-06-02 US disclosed
US-20160024104-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-28 US disclosed
US-20160015690-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2016-01-21 US disclosed
US-9096586-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-08-04 US disclosed
US-9006229-B2 Benzothiazole compounds and their pharmaceutical use GILEAD SCIENCES, INC. (US) 2015-04-14 US disclosed
US-8987250-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2015-03-24 US disclosed
US-20140045818-A1 BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE GILEAD SCIENCES, INC. (US) 2014-02-13 US disclosed
US-20130281433-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2013-10-24 US disclosed
US-20130281434-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170088554-A1 THERAPEUTIC COMPOUNDS FURIN, NFATC1, NPC1 ACHE 4284/4885AKR1C3 51/4885AKR1C2 34/4885
US-20140045818-A1 BENZOTHIAZOLE COMPOUNDS AND THEIR PHARMACEUTICAL USE FURIN, NFATC1, RUNX1 ACHE 4391/4885AKR1C3 466/4885AKR1C2 205/4885
US-20130281434-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, CD4 ACHE 3621/4885AKR1C3 262/4885AKR1C2 176/4885
US-20160024104-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, NPC1 ACHE 4327/4885AKR1C3 50/4885AKR1C2 33/4885
US-20160015690-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 ACHE 849/4885AKR1C3 1169/4885AKR1C2 1566/4885
US-20130281433-A1 THERAPEUTIC COMPOUNDS NQO1, HAVCR2, CCR5 ACHE 849/4885AKR1C3 1169/4885AKR1C2 1566/4885
US-20160152582-A1 THERAPEUTIC COMPOUNDS NFATC1, FURIN, CD4 ACHE 3621/4885AKR1C3 262/4885AKR1C2 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.